1a.Objectives (from AD-416):
The objective will be to develop, expedite the evaluation and standardization of Rift Valley fever (RVF) diagnostic assays and vaccine control strategies.
1b.Approach (from AD-416):
This project will utilize the vector-borne disease expertise of the ARS, Arthropod-Borne Animal Diseases Research Laboratory (ABADRL) and the Rift Valley fever (RVF) diagnostic expertise of the National Institute for Communicable Diseases NICD to develop, evaluate, and standardize diagnostic assays and vaccines for RVF. The collaborative project will evaluate existing and newly developed diagnostic tests such as various viral genome amplification assays (real-time RT-PCR, RT-LAMP, and LATE-PCR) and enzyme-linked immunosorbent assays (ELISA) based on recombinant antigens (RVF-N, -G2, and –NSs). This will be achieved by direct comparison of available assays in both field-deployable and diagnostic laboratory based formats. The goal is to provide recommendations for standardized diagnostics that can be universally applied by international disease outbreak response teams. The collaborative project will also evaluate existing and newly developed vaccines for RVF.
This project was initiated to develop, expedite the evaluation and standardization of Rift Valley fever (RVF) diagnostic assays and vaccine control strategies. This project resulted in generating important supportive data for the ARS RVF quadruplex assay that would not have been able to obtain otherwise. The prototype lateral flow serological and antigen capture assays were also evaluated and performed very well.